John Fish, MD
Vascular Surgery · Toledo, OHNPI 1982819579
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $43,125 of the $57,708 with a category attached, or 74.7%. Johnson & Johnson accounts for 86.9% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2019 at $26,036 and has fallen 90.8% since, to $2,391 in 2025. Among vascular surgery clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 260 payments — averaging $221.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$50K
- Smith+Nephew$3K
- Tactile Systems Technology Inc$748
- E.r. Squibb & Sons, L.L.C.$669
- Bard Peripheral Vascular, Inc.$530
- Medtronic$493
- plus $2K from 19 others
Across 2 payments — averaging $4828.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$8K
- Dova Pharmaceuticals$2K
What the payments were for
- Consulting fees$1,0502%
- Speaking & faculty fees$43,12575%
- Travel & lodging$6,69212%
- Food & beverage$6,54011%
- Education$3011%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 117 | $50,173 |
| Smith+Nephew | 27 | $3,469 |
| Tactile Systems Technology Inc | 10 | $748 |
| E.r. Squibb & Sons, L.L.C. | 24 | $669 |
| Bard Peripheral Vascular, Inc. | 11 | $530 |
| Medtronic(2 entities) | 18 | $493 |
| Pfizer | 13 | $234 |
| Kerecis Limited | 5 | $229 |
| Lemaitre Vascular, Inc. | 2 | $192 |
| Zimvie Inc. | 1 | $150 |
| Janssen Scientific Affairs, LLC | 1 | $125 |
| Boston Scientific | 5 | $113 |
| Novartis | 5 | $109 |
| Organogenesis Inc. | 4 | $81 |
| Bsn Medical Inc | 3 | $68 |
| Davol Inc. | 2 | $59 |
| Portola Pharmaceuticals, LLC | 2 | $57 |
| Angiodynamics, Inc. | 2 | $43 |
| Mimedx Group, Inc. | 1 | $37 |
| Integra Lifesciences Corporation | 1 | $31 |
| Inari Medical, Inc. | 2 | $29 |
| Aroa Biosurgery Incorporated | 1 | $23 |
| Vertex | 1 | $22 |
| Biocompatibles, Inc. | 1 | $13 |
| W. L. Gore & Associates, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$48,132
- PICO$2,242
- Versajet$1,708
- Grafix$1,474
- ACTICOAT 4" X 4"$933
- Allevyn Gentle Border 10 x 10cm Ctn 10$933
- Oasis$933
- COLLAGENASE SANTYL$775
- Kerecis SurgiClose$512
- Flexitouch Plus$500
- ENTRE$500
- ELIQUIS$383
- Diem2-RevitaliZe$150
- VENOVO$141
- Kerecis GraftGuide$128
How this compares
$57,708 in reported general payments places this provider in the 95th percentile of 213 vascular surgery providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 576 | $468,090 |
| XareltoRivaroxaban | 210 | $201,067 |
| Enoxaparin Sodium | 28 | $5,225 |
| Warfarin Sodium | 158 | $1,457 |
| Pentoxifylline | 38 | $1,185 |
| ClopidogrelClopidogrel Bisulfate | 46 | $790 |
| Cilostazol | 26 | $574 |
| Atorvastatin Calcium | 42 | $415 |
| Gabapentin | 20 | $402 |
| Rosuvastatin Calcium | 24 | $241 |
| JantovenWarfarin Sodium | 13 | $178 |
| Triamcinolone Acetonide | 18 | $134 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 17 | $19 |
| Diazepam | 17 | $8 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $234 | $468,090576 claims |
| Johnson & JohnsonXarelto | $50,173 | $201,067210 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 213 vascular surgery providers in Ohio.
Other vascular surgery in Toledo
- John PigottToledo$65K
- Mohamed OsmanToledo$25K
- Franklin FaridToledo$13K
- Brett AplinToledo$12K
- David VicenteToledo$10K
- Gregory WalkerToledo$10K
- Patrick MuckCincinnati$650K
- Sean LydenCleveland$561K
- Brian KuhnCincinnati$184K
- Vikram RaoWilloughby$137K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.